Israel Englander Zentalis Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 3,069,514 shares of ZNTL stock, worth $3.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,069,514

Previous 957,563 220.55%

Holding current value

$3.87 Million

Previous $2.9 Million 68.22%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.59 - $3.24 $3.36 Million - $6.84 Million	2,111,951 Added 220.55%	3,069,514 $4.88 Million
Q4 2024 Feb 14, 2025	BUY	$2.7 - $4.03 $192,987 - $288,052	71,477 Added 8.07%	957,563 $2.9 Million
Q3 2024 Nov 14, 2024	BUY	$2.9 - $4.57 $1.43 Million - $2.26 Million	493,478 Added 125.69%	886,086 $3.25 Million
Q2 2024 Aug 14, 2024	BUY	$4.09 - $16.13 $598,309 - $2.36 Million	146,286 Added 59.39%	392,608 $1.61 Million
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $2.34 Million - $3.56 Million	215,627 Added 702.48%	246,322 $3.88 Million
Q4 2023 Feb 14, 2024	SELL	$9.84 - $20.13 $1.55 Million - $3.17 Million	-157,625 Reduced 83.7%	30,695 $465,000
Q2 2023 Aug 14, 2023	BUY	$17.41 - $30.05 $2.77 Million - $4.78 Million	158,926 Added 540.67%	188,320 $5.31 Million
Q1 2023 May 15, 2023	SELL	$16.14 - $24.94 $45,062 - $69,632	-2,792 Reduced 8.67%	29,394 $506,000
Q4 2022 Feb 14, 2023	SELL	$18.07 - $25.6 $1.24 Million - $1.75 Million	-68,486 Reduced 68.03%	32,186 $648,000
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $2.04 Million - $3.19 Million	100,672 New	100,672 $2.18 Million

Others Institutions Holding ZNTL

# of Institutions

140

Shares Held

59.1M

Call Options Held

7.9K

Put Options Held

42.5K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $71.8M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account